Research ArticleAsthma

Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production

See allHide authors and affiliations

Science Translational Medicine  02 Jul 2014:
Vol. 6, Issue 243, pp. 243ra85
DOI: 10.1126/scitranslmed.3008961

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Asthma Antibody Clears the Air

A humanized antibody may be the key for treating allergic asthma. Gauvreau et al. report that quilizumab—a humanized monoclonal antibody that targets the membrane immunoglobulin E (IgE) B cell receptor—led to reductions in total and allergen-specific serum IgE that were sustained for 6 months after dosing and were associated with improvements in allergen-induced early and late asthmatic airway responses. A monoclonal antibody that neutralizes IgE can effectively treat asthma in the clinic; however, use is limited by dosing restrictions and it does not prevent new IgE production. Inhibiting IgE production by targeting membrane IgE–expressing cells may enable more subjects to be treated and less frequent dosing, and has the potential for sustained effects upon the cessation of therapy.